INVO Fertility, Inc. (IVF) 주식 분석

회사 개요

INVO Fertility, Inc. operates as a healthcare services company dedicated to the fertility marketplace by providing assisted reproductive technology care to patients. The company's business model is executed through three distinct segments: Fertility Clinic Services, the INVOcell Device, and Therapeutics. This entity functions within the broader Healthcare sector and specifically within the Medical Devices industry, focusing on specialized reproductive health solutions. The company currently maintains a market capitalization of $13.99M and generates annual revenue of $6.94M with an employee base of 33. These valuation and revenue figures indicate that the company operates as a micro-cap entity with a very small scale relative to larger industry peers, suggesting a niche market position that relies heavily on operational efficiency to manage its limited financial resources.

재무 건전성

The company reported revenue of $6.94M over the trailing twelve months, yet this revenue generated a net income of $-11,220,118, revealing a significant structural cost burden where expenses far exceed earnings before tax adjustments. Before tax adjustments, the EBITDA stands at $-7,119,142, indicating that core operations are currently cash-burning despite top-line generation. However, the company demonstrates a positive free cash flow of $950,669, which provides a degree of financial flexibility by generating cash from operations that exceeds capital expenditures, allowing for potential debt repayment or strategic reinvestment despite accounting losses. The gross margin stands at 39.2%, indicating that the cost of goods sold consumes roughly 60.8% of revenue, which is typical for medical device manufacturing but leaves limited room for error. In contrast, the operating margin is -93.1% and the profit margin is 0.0%, highlighting that general and administrative expenses are aggressively high, eroding nearly all operating income before interest and taxes. The company holds $355,891 in cash against $4.23M in debt, resulting in a debt-to-equity ratio of 72.39, which characterizes a highly leveraged balance sheet that relies heavily on equity financing or capital markets to service obligations. Furthermore, the current ratio is 0.12, a metric that signals severe short-term liquidity constraints where current liabilities significantly outweigh current assets, posing a risk regarding the ability to meet immediate financial obligations. The return on equity is N/A due to the capital structure, while the return on assets is -48.4%, revealing that the company's asset base is currently generating negative returns and failing to create value for stakeholders.

밸류에이션 평가

The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.09, a discrepancy that implies the market is pricing the stock based on future expectations rather than current profitability, though negative forward P/E values often indicate continued expected losses. The price-to-book ratio is -0.09, a negative figure that indicates the market values the company at a fraction of its book value or suggests accounting adjustments that have resulted in a negative equity position relative to market price. The price-to-sales ratio is 2.01, and the EV/EBITDA is -1.90, suggesting that valuation multiples are being driven by revenue growth potential rather than earnings power, as traditional earnings-based multiples are not applicable. The stock has traded between a 52-week high of $384.00 and a 52-week low of $1.93, meaning the current price sits in the lower end of this range given the company's current financial distress signals. The beta is N/A, indicating that historical volatility data relative to the broader market is not available or statistically insignificant, making it difficult to assess the stock's sensitivity to market movements based on this specific metric.

Growth & Income

The company achieved a revenue growth rate of 22.6% year-over-year, while earnings growth is N/A due to the absence of positive net income, implying that top-line expansion has not yet translated into profitability and that the path to positive earnings remains uncertain. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings, including those from operations, are retained within the business to fund growth initiatives or reduce debt rather than being distributed to shareholders. This reinvestment strategy is necessary given the high cash burn rate and leveraged balance sheet, as distributing capital would further compromise financial stability. Overall, the growth and income profile reflects a high-risk, high-potential scenario where rapid revenue expansion is occurring, but the lack of earnings growth and dividend income necessitates a reliance on external capital or operational turnaround to achieve sustainable financial performance.